Fresenius Kabi is recalling two lots of the sedative dexmedetomidine due to the possibility of cross-contamination with lidocaine, the FDA said July 22.
The FDA said its investigation shows that only the two recalled lots were potentially contaminated, and no adverse event reports have been received.
The agency said that administering dexmedetomidine with trace amounts of lidocaine to a patient could cause anaphylaxis, which can be life-threatening.
Read the FDA's full news release here.